Native Cardio
Native Cardio Inc. is a late-stage medical device company dedicated to improving patient quality of life through innovative, minimally invasive, and cost-efficient solutions that address unmet healthcare needs, particularly focusing on atrial fibrillation and postoperative atrial fibrillation (POAF). The company develops advanced technologies such as low-energy cardioversion devices and targeted tissue delivery systems to treat cardiac arrhythmias effectively and safely.
Industries
Nr. of Employees
small (1-50)
Native Cardio
3175 State Route 10 East Suite 1003, Denville, NJ 07834, United States of America
Patents
Products
Ultra‑low energy atrial cardioversion and targeted delivery system
A medical device concept designed to deliver ultra‑low electrical cardioversion energy and optionally localized drug therapy directly to atrial tissue via a transthoracic approach to treat postoperative atrial fibrillation.
Ultra‑low energy atrial cardioversion and targeted delivery system
A medical device concept designed to deliver ultra‑low electrical cardioversion energy and optionally localized drug therapy directly to atrial tissue via a transthoracic approach to treat postoperative atrial fibrillation.
Services
Partnerships with clinical investigators and health technology companies to support clinical studies, monitoring and combined diagnostic‑therapeutic workflows.
Partnerships with clinical investigators and health technology companies to support clinical studies, monitoring and combined diagnostic‑therapeutic workflows.
Expertise Areas
- Clinical trial management and investigator-sponsored research
- Cardiac rhythm management and atrial fibrillation treatment
- Medical device research and systems engineering
- Transthoracic targeted tissue delivery
Key Technologies
- Ultra-low-energy cardioversion
- Transthoracic targeted tissue drug delivery
- Direct atrial tissue delivery systems
- Wireless ECG patch monitoring integration
News & Updates
Native Cardio team members publish with IntechOpen on its new book titled, Endocarditis - Diagnosis and Treatment.
An analysis of five U.S. medical claims databases suggests as many as 23% of 5.6 million to 6.6 million presumptive atrial fibrillation cases are undiagnosed, with many undiagnosed patients likely eligible for oral anticoagulant treatment.
Native Cardio collaborates with Peerbridge Health to develop solutions for better diagnosis and treatment of atrial fibrillation and POAF, including wireless ECG patches and ultra-low shock devices.
Native Cardio was recognized as a finalist for the 5th Annual Citeline Awards in the category of Most Innovative Start-up, highlighting its novel medical device for treating postoperative atrial fibrillation.
Finalist for the 5th Annual Citeline Awards in the category of Most Innovative Start-up.
Native Cardio team members publish with IntechOpen on its new book titled, Endocarditis - Diagnosis and Treatment.
An analysis of five U.S. medical claims databases suggests as many as 23% of 5.6 million to 6.6 million presumptive atrial fibrillation cases are undiagnosed, with many undiagnosed patients likely eligible for oral anticoagulant treatment.
Native Cardio collaborates with Peerbridge Health to develop solutions for better diagnosis and treatment of atrial fibrillation and POAF, including wireless ECG patches and ultra-low shock devices.
Native Cardio was recognized as a finalist for the 5th Annual Citeline Awards in the category of Most Innovative Start-up, highlighting its novel medical device for treating postoperative atrial fibrillation.
Finalist for the 5th Annual Citeline Awards in the category of Most Innovative Start-up.